A detailed history of Sargent Investment Group, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Sargent Investment Group, LLC holds 9,269 shares of BMY stock, worth $521,103. This represents 0.09% of its overall portfolio holdings.

Number of Shares
9,269
Holding current value
$521,103
% of portfolio
0.09%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$39.66 - $51.75 $367,608 - $479,670
9,269 New
9,269 $479,000
Q4 2023

Feb 05, 2024

SELL
$48.48 - $57.85 $195,132 - $232,846
-4,025 Reduced 41.21%
5,741 $294,000
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $30,160 - $33,724
521 Added 5.64%
9,766 $566,000
Q2 2023

Jul 31, 2023

SELL
$63.71 - $70.74 $10,002 - $11,106
-157 Reduced 1.67%
9,245 $591,000
Q1 2023

May 02, 2023

BUY
$65.71 - $74.53 $4,928 - $5,589
75 Added 0.8%
9,402 $651,000
Q3 2022

Oct 26, 2022

SELL
$0.13 - $76.84 $57 - $34,270
-446 Reduced 4.56%
9,327 $655,000
Q2 2022

Jul 26, 2022

SELL
$72.62 - $79.98 $67,536 - $74,381
-930 Reduced 8.69%
9,773 $753,000
Q1 2022

May 06, 2022

BUY
$61.48 - $73.72 $7,131 - $8,551
116 Added 1.1%
10,703 $782,000
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $19,306 - $22,507
-360 Reduced 3.29%
10,587 $660,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $19,821 - $23,218
335 Added 3.16%
10,947 $648,000
Q2 2021

Aug 05, 2021

BUY
$61.91 - $67.42 $928 - $1,011
15 Added 0.14%
10,612 $709,000
Q1 2021

May 04, 2021

BUY
$59.34 - $66.74 $119,688 - $134,614
2,017 Added 23.51%
10,597 $669,000
Q4 2020

Feb 10, 2021

BUY
$57.74 - $65.43 $253,767 - $287,564
4,395 Added 105.02%
8,580 $532,000
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $240,344 - $266,333
4,185 New
4,185 $252,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Sargent Investment Group, LLC Portfolio

Follow Sargent Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Investment Group, LLC with notifications on news.